Amir H Shemirani
Overview
Explore the profile of Amir H Shemirani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadeghi F, Sarkady F, Zsori K, Szegedi I, Orban-Kalmandi R, Szekely E, et al.
J Pers Med
. 2022 Jul;
12(8).
PMID: 35893315
(1) Background: Ischemic stroke is one of the leading causes of death and disability. An inflammatory response is observed in multiple stages of cerebral ischemia, particularly in the acute phase....
2.
Bogati R, Katona E, Shemirani A, Balogh E, Bardos H, Jeney V, et al.
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628664
Plasma factor XIII (pFXIII) is a heterotetramer of FXIII-A and FXIII-B subunits. The cellular form (cFXIII), a dimer of FXIII-A, is present in a number of cell types. Activated FXIII...
3.
Orosz Z, Bardos H, Shemirani A, Debreceni I, Lassila R, Riikonen A, et al.
Int J Mol Sci
. 2019 Dec;
20(23).
PMID: 31783511
Cellular factor XIII (cFXIII, FXIII-A), a transglutaminase, has been demonstrated in a few cell types. Its main function is to cross-link proteins by isopeptide bonds. Here, we investigated the presence...
4.
Kovacs S, Csiki Z, Zsori K, Bereczky Z, Shemirani A
Platelets
. 2017 Dec;
30(2):139-147.
PMID: 29252063
The purpose of this study was to evaluate the association between platelet (PLT) count and mean platelet volume (MPV) and venous thromboembolism (VTE). Thus, this study reviewed and performed a...
5.
Shemirani A
Eur Arch Otorhinolaryngol
. 2016 Apr;
273(11):4039.
PMID: 27098614
No abstract available.
6.
Homorodi N, Kovacs E, Lee S, Katona E, Shemirani A, Haramura G, et al.
J Transl Med
. 2016 Mar;
14:74.
PMID: 26980433
Background: Aspirin resistance established by different laboratory methods is still a debated problem. Using COX1 specific methods no aspirin resistance was detected among healthy volunteers. Here we tested the effect...
7.
Zsori K, Muszbek L, Csiki Z, Shemirani A
Int J Mol Sci
. 2013 Feb;
14(2):3456-66.
PMID: 23389042
RT-qPCR is the standard method for studying changes in relative transcript level in different experimental and clinical conditions and in different tissues. No validated reference genes have been reported for...
8.
Csiki Z, Garai I, Shemirani A, Papp G, Zsori K, Andras C, et al.
Microvasc Res
. 2011 Apr;
82(1):84-7.
PMID: 21515290
Objectives: Calcium channel inhibitors have beneficial impact on microcirculation, but beta-blocker effect is controversial. Clinicians still do not agree on beta-blocker combination with other treatments in the management of impaired...
9.
Shemirani A, Pongracz E, Antalfi B, Adany R, Muszbek L
Thromb Res
. 2010 Jul;
126(2):159-62.
PMID: 20609463
Introduction: Factor XIII (FXIII) is a key regulator of fibrinolysis and clot firmness. Val34Leu polymorphism of its potentially active A subunit (FXIII-A) leads to faster activation of FXIII, influences clot...
10.
Muszbek L, Bereczky Z, Bagoly Z, Shemirani A, Katona E
Semin Thromb Hemost
. 2010 Apr;
36(1):18-33.
PMID: 20391293
Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly alpha (2) plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by...